Table 1. Progress made for iMCD... | American Society of Hematology

Table 1.

Progress made for iMCD research, 2012-2018

State of iMCD research in 2012	State of iMCD research in 2018
Research coordination
No physician, researcher, or patient communities	400+ physicians and researchers connected through the CDCN and 2000+ patients connected virtually and through annual meetings
No registry or biorepository	ACCELERATE Natural History Registry and Biorepository are enrolling patients around the world via e-consent
Defining iMCD
Different subclassification systems being used	Uniform classification system published in Blood¹
No diagnostic criteria for iMCD	International, evidence-based diagnostic criteria published in 2017¹³
Characterizing pathogenesis of iMCD and advancing treatment options
Prevailing model of pathogenesis: an IL-6 secreting, lymph node “tumor” disorder	New model guiding research: complex cytokine storm disorder with an unknown etiology; several hypothesized etiologies under intense investigation
No genomic alterations identified in iMCD	First somatic mutation in iMCD published in 2018²⁰; other candidates are currently undergoing validation
No FDA-approved treatments for iMCD	Siltuximab became the first and only FDA-approved treatment of iMCD in 2014
No treatment guidelines	International, evidence-based treatment guidelines in press³⁹
No drugs in development directed at any targets other than IL-6	First clinical trial of relapsed/refractory iMCD with a drug directed at a target other than IL-6/IL-6R expected to begin enrollment in 2019

State of iMCD research in 2012	State of iMCD research in 2018
Research coordination
No physician, researcher, or patient communities	400+ physicians and researchers connected through the CDCN and 2000+ patients connected virtually and through annual meetings
No registry or biorepository	ACCELERATE Natural History Registry and Biorepository are enrolling patients around the world via e-consent
Defining iMCD
Different subclassification systems being used	Uniform classification system published in Blood¹
No diagnostic criteria for iMCD	International, evidence-based diagnostic criteria published in 2017¹³
Characterizing pathogenesis of iMCD and advancing treatment options
Prevailing model of pathogenesis: an IL-6 secreting, lymph node “tumor” disorder	New model guiding research: complex cytokine storm disorder with an unknown etiology; several hypothesized etiologies under intense investigation
No genomic alterations identified in iMCD	First somatic mutation in iMCD published in 2018²⁰; other candidates are currently undergoing validation
No FDA-approved treatments for iMCD	Siltuximab became the first and only FDA-approved treatment of iMCD in 2014
No treatment guidelines	International, evidence-based treatment guidelines in press³⁹
No drugs in development directed at any targets other than IL-6	First clinical trial of relapsed/refractory iMCD with a drug directed at a target other than IL-6/IL-6R expected to begin enrollment in 2019